First-line treatment for advanced NSCLC in older patients and those with poor performance status
Mené en France sur 216 patients âgés atteints d'un cancer du poumon non à petites cellules de stade avancé et présentant un statut de performance ECOG de 2 (âge médian : 74 ans), cet essai multicentrique de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité de deux traitements de première ligne, l'un par nivolumab/ipilimumab et l'autre par doublet de chimiothérapie à base de sels de platine
In the past 5 years, the implementation of immune checkpoint inhibitors has substantially altered clinical management for patients with locally advanced or metastatic, driver gene-negative non-small-cell lung cancer (NSCLC). However, a considerable gap in prospective research exists regarding the application of immunotherapy for patients with NSCLC who are aged 75 years or older or who have an Eastern Cooperative Oncology Group (ECOG) performance status of 2. Little robust evidence is available from randomised phase 3 trials to confirm the safety and efficacy of such treatments in these patient groups, therefore the medical community has relied primarily on retrospective studies to explore these crucial aspects.
The Lancet Respiratory Medicine , commentaire, 2023